A partner in the Tax Department, Kiran Sheffrin focuses her practice on advising clients on the tax and structuring aspects of mergers and acquisitions, spin‑offs and other divestitures, restructurings, joint ventures and financing transactions, both in the United States and in connection with cross-border transactions. She also advises clients during the course of tax controversy with various tax authorities. Kiran’s work spans many industry sectors, with significant depth in pharmaceuticals, consumer products, telecommunications and technology. She was named a “Rising Star” by Law360 in 2024, recognizing her as one of five outstanding tax lawyers in the nation under the age of 40, and in 2023, she was shortlisted for the “Rising Star: Tax” award at Euromoney Legal Media Group’s Americas Women in Business Law Awards.
Kiran’s recent representative matters include advising:
- AmerisourceBergen in its $6.5 billion acquisition of Walgreens’ Alliance Healthcare businesses
- Anheuser-Busch InBev in its $123 billion acquisition of SABMiller and the $12 billion sale of SABMiller’s U.S. and global Miller-branded businesses to Molson Coors and an asset swap with Ambev in which AB InBev transferred SABMiller’s Panamanian business to Ambev and Ambev transferred its business in Colombia, Peru and Ecuador to AB InBev
- Artel in its acquisition by Advanced Instruments
- Avon in its $3.7 billion acquisition by Natura and Avon North America in its $125 million acquisition by LG Household and Healthcare
- Axalta in its $25 billion merger of equals with Akzo Nobel
- BDT and its affiliates in connection with multiple matters, including the acquisition of a majority interest in Alliance Laundry Systems from Ontario Teachers’ Pension Plan
- Cable One in its strategic partnership with Mega Broadband
- Cincinnati Bell in its $2.9 billion acquisition by Macquarie Infrastructure, its $650 million combination with Hawaii Telecom and its $201 million acquisition of OnX Enterprise Solutions
- Conduent in the sale of a business to Alinda Capital Partners and the sale of a business to H.I.G. Capital
- Dentsu Aegis in its acquisition of Merkle
- DRI Capital and its affiliates in connection with its:
- acquisition of a royalty interest in Orserdu from Eisai, its acquisition of a second royalty interest in Orserdu from Radius Health, the $210 million sale of its TZIELD royalty interest to Sanofi and two offerings of units totaling C$201.7 million
- acquisition of a synthetic royalty interest in the Worldwide Sales of Sebetralstat and its equity investment in KalVista Pharmaceuticals
- Eurazeo in its acquisition of Scaled Agile
- The Fresh Market in its $1.36 billion sale to affiliates of Apollo
- GasLog in its take‑private transaction with BlackRock’s Global Energy & Power Infrastructure Fund
- IBM in numerous transactions, including its acquisitions of the Adobe Workfront consultancy, Agile 3 Solutions, BoxBoat Technologies, the technology assets from Catalogic Software, Databand.ai, McD Tech Labs from McDonald’s, Polar Security, Randori, ReaQta, Sentaca and Hakkoda
- Legal & General in its investment in Taurus Investment Holdings
- Lindsay Goldberg and American Securities in the $2.405 billion acquisition of AECOM’s Management Services business, as well as Lindsay Goldberg in its acquisitions of Fleetwood-Fibre Packaging & Graphics and Allpak Container
- New Senior in its $2.3 billion acquisition by Ventas
- The underwriters in the IPO of On Holding
- Orbotech in its $3.4 billion sale to KLA‑Tencor
- Parker Hannifin in its $3.67 billion acquisition of LORD
- RELX Group in its £580 million acquisition of ThreatMetrix, its acquisition of Safe Banking Systems and its acquisition of Aries Systems
- Route Mobile and its founding shareholders in the pending ₹59.22 billion sale of a majority stake in Route Mobile to Proximus Group
- Spectranetics in its €1.9 billion sale to Phillips
- Unilever in its $384 million acquisition of TAZO from Starbucks, its acquisition of Seventh Generation and its acquisition of Sundial Brands
- Valvoline in the $2.65 billion sale of its Global Products business to Aramco
- Viatris in its divestitures totaling $6.94 billion in value, including the $3.335 billion combination of its biosimilars portfolio with Biocon Biologics and the divestitures of its Over‑the‑Counter, Women’s Healthcare and Active Pharmaceutical Ingredients businesses, and in the $750 million acquisitions of Oyster Point and Famy Life Sciences, as well as Mylan in its $50 billion combination with Upjohn, a division of Pfizer, to form Viatris, its $9.9 billion acquisition of Meda, its $5.6 billion inversion acquisition of Abbott Laboratories’ non‑U.S. developed markets specialty and branded generics business, its acquisition of the non‑sterile, topicals‑focused specialty and generics business of Renaissance Acquisition Holdings for $950 million in cash at closing plus additional contingent payments of up to $50 million and its proposal to acquire Perrigo in a transaction valued at approximately $35 billion
- Vista Outdoor in its acquisition of Camp Chef
- White Mountain in its acquisition of a majority stake in Bamboo Ide8 Insurance Services and later $1.75 billion sale to CVC
*Includes matters handled prior to joining Paul, Weiss
